NovoCure Limited

News & Events

Press Releases

In The Media

1. Novocure Announces Upcoming Investor Events

   Business Wire MAY 27, 2025 7:00 AM EDT
   Novocure (NASDAQ: NVCR) announced today that management will participate in two upcoming investor...
   READ ARTICLE

2. Novocure Reports First Quarter 2025 Financial Results

   Business Wire APR 24, 2025 7:00 AM EDT
   Quarterly net revenues of $155 million, up 12% year-over-year, with 4,268 active patients on ther...
   READ ARTICLE

3. Novocure to Present Results from the Phase 3 PANOVA-3 Clinical Trial of its Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer as a Late-Breaking Oral Presentation at the 2025 ASCO Annual Meeting

   Business Wire APR 23, 2025 10:16 AM EDT
   Novocure (NASDAQ: NVCR) announced today that it will present additional results from the Phase 3 ...
   READ ARTICLE

4. Novocure's Optune Lua® Receives CE Mark Approval for the Treatment of Metastatic Non-Small Cell Lung Cancer

   Business Wire APR 22, 2025 7:09 AM EDT
   Optune Lua is now approved for use concurrently with immune checkpoint inhibitors or docetaxel in...
   READ ARTICLE

5. Novocure to Report First Quarter 2025 Financial Results

   Business Wire APR 1, 2025 7:00 AM EDT
   Novocure (NASDAQ: NVCR) will report financial results for the first quarter 2025 on April 24, 202...
   READ ARTICLE

6. Novocure to Participate in Leerink Partners 2025 Global Healthcare Conference

   Business Wire MAR 4, 2025 7:00 AM EST
   Novocure (NASDAQ: NVCR) announced today that management will participate in the Leerink Global He...
   READ ARTICLE

7. Novocure Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Company Update

   Business Wire FEB 27, 2025 7:00 AM EST
   Full year 2024 net revenues of $605 million and fourth quarter net revenues of $161 million ...
   READ ARTICLE

8. Novocure Inaugurates New Global Headquarters in Canton of Zug, Switzerland

   Business Wire JAN 22, 2025 4:00 AM EST
   New headquarters supports Novocure’s continued growth as it pursues its mission of extendi...
   READ ARTICLE

9. Novocure Announces Preliminary Full Year and Fourth Quarter 2024 Performance and Provides Company Update

   Business Wire JAN 13, 2025 7:00 AM EST
   Preliminary full year 2024 net revenues of $605 million and fourth quarter net revenues of $161 m...
   READ ARTICLE

10. Novocure to Participate in 43rd Annual J.P. Morgan Healthcare Conference

    Business Wire JAN 3, 2025 7:00 AM EST
    Novocure (NASDAQ: NVCR) announced today that management will participate in the 43 rd Annual ...
    READ ARTICLE